BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

Company Unveils Phase II/III Relatlimab Combo Data At ASCO

 
• By Alaric DeArment
  
Sun screen
BMS' anti-LAG3 antibody shows safety benefit combined with Opdivo compared with Opdivo/Yervoy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences